SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

RVPH

Reviva Pharmaceuticals
NEUTRAL
Impact 4/10
Horizonweeks Processed3d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The key catalyst is FDA feedback on the new brilaroxazine formulation expected in Q4 2026, which will determine the path for the RECOVER-2 trial and NDA submission. The company's cash runway of $17.5 million is limited, and patient enrollment is explicitly contingent on additional financing, making the capital raise timeline critical to watch alongside the FDA feedback.

DirectionNeutral
Confidencehigh
Horizonweeks

brilaroxazine

◆ Mixed Named in this press release
Impact
Phase
Phase 3
Time to market
If approved, brilaroxazine is at least 3-5 years from potential commercialization. RECOVER-2 enrollment is expected to begin in 1H 2027 (subject to financing), followed by a multi-year trial, NDA submission, and FDA review.
Next catalyst
None dated

What to watchThe immediate catalyst is FDA feedback on the new brilaroxazine formulation, expected in Q4 2026 (any day now). Positive feedback would clear a path for RECOVER-2 and NDA; negative feedback or a request for more data would likely pressure the stock further. Separately, the company needs to raise additional capital before RECOVER-2 enrollment can begin in 1H 2027, and its OTCQB listing limits financing options.

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva reported Q3 2026 net loss of $2.3 million ($0.17 per share), narrower than the $4.0 million loss in Q3 2025 and slightly better than the consensus estimate of a $0.18 loss. The company highlighted FDA feedback expected in Q4 2026 on a new brilaroxazine formulation for the RECOVER-2 Phase 3 trial, with patient enrollment contingent on additional financing, and a patent application granted priority examination potentially extending protection through 2046.

Key Financial Metrics

EPS
−$0.17
est −$0.18 · +5.6%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Net loss of $2.3 million ($0.17 per share) for Q3 2026 vs. $4.0 million ($1.09 per share) in Q3 2025
  • Cash and cash equivalents $17.5 million as of September 30, 2026, up from $14.4 million at year-end 2025
  • FDA feedback on new brilaroxazine formulation expected in Q4 2026
  • Bioequivalence study for new formulation expected to start Q1 2027
  • RECOVER-2 Phase 3 patient enrollment expected to begin in 1H 2027, subject to additional financing
  • Composition of matter patent application for new formulation granted priority examination (Track 1), potential patent extension through 2046
  • Company anticipates filing for Nasdaq relisting in 1H 2027
  • Shares outstanding increased to 13.1 million from 5.9 million at year-end 2025, reflecting reverse stock split and capital raises

Financial Impact

Net loss improved by $1.7 million year-over-year; cash position increased by $3.0 million since year-end 2025

net losscashoperating expenses

Risk Factors

  • Patient enrollment in RECOVER-2 is subject to additional financing, creating execution risk
  • Stock trades on OTCQB with limited liquidity; Nasdaq relisting application not until 1H 2027
  • Pre-revenue biotech with no approved products; depends entirely on clinical and regulatory milestones
  • New formulation introduces regulatory uncertainty pending FDA feedback

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402358

Track record

12 reports on RVPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $0.3400 Now $0.3504 +3.07% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (10h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026